Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.
Nikolaos Stalikas, Takuya Mizukami, Frederic Bouisset...
https://pubmed.ncbi.nlm.nih.gov/41195772/Actively Recruiting
Led by CoreAalst BV · Updated on 2026-01-12
2500
Participants Needed
29
Research Sites
208 weeks
Total Duration
Researchers are evaluating the use of a new device called the pressure microcatheter to measure the severity of coronary artery lesions in patients with stable coronary artery disease or stabilized non-ST elevation acute coronary syndrome ACS. This trial compares clinical outcomes of patients guided by the pressure microcatheter versus those guided by the conventional pressure wire during percutaneous coronary intervention PCI. The study aims to determine if the pressure microcatheter strategy is not worse than the pressure wire strategy for clinical decision making. Participants will be randomly assigned to receive PCI guided by either the pressure microcatheter or the pressure wire. After an angiographically successful PCI, patients will either undergo fractional flow reserve FFR-guided stent optimization using the assigned device or receive standard care treatment. The interventions are compared in four groups pressure microcatheter with optimization, pressure wire with optimization, pressure microcatheter with standard care, and pressure wire with standard care. Participants will be followed in hospital initially, then at 12 months, and yearly up to five years to monitor clinical outcomes. The study involves collecting data on major adverse cardiac events MACE, procedural times, resource use during hospitalization, post-PCI FFR measurements, and rates of symptoms and complications. This follow-up aims to assess safety, effectiveness, and long-term results of the two guidance strategies.
CONDITIONS
INSIGHTFUL-FFR Clinical Trial
S
Sofie Pardaens
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
CoreAalst BV
Lead Sponsor
Insight Lifetech Co., Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During hospitalization from admission to discharge after PCI procedure
Participants undergo percutaneous coronary intervention (PCI) guided by either Pressure Microcatheter or Pressure Wire strategies. After PCI, participants receive either FFR-guided stent optimization or standard of care treatment based on their randomized group.
1 hospital stay including the PCI procedure and post-procedure care
Duration - 12 months
Participants are monitored for clinical outcomes including major adverse cardiac events and vessel-related events over 12 months following treatment.
Scheduled visits during the 12 months follow-up period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Nikolaos Stalikas, Takuya Mizukami, Frederic Bouisset...
https://pubmed.ncbi.nlm.nih.gov/41195772/CoreAalst BV
Lead Sponsor
Insight Lifetech Co., Ltd.
Collaborating Sponsor